Guggenheim Maintains Neutral on Amgen, Raises Price Target to $435
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice TargetHot
Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $378 to $435.
Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $378 to $435.